Pakker N G, Kroon E D, Roos M T, Otto S A, Hall D, Wit F W, Hamann D, van der Ende M E, Claessen F A, Kauffmann R H, Koopmans P P, Kroon F P, ten Napel C H, Sprenger H G, Weigel H M, Montaner J S, Lange J M, Reiss P, Schellekens P T, Miedema F
Department of Clinical Viro-Immunology, CLB, Sanquin Blood Supply Foundation, University of Amsterdam, The Netherlands.
AIDS. 1999 Feb 4;13(2):203-12. doi: 10.1097/00002030-199902040-00008.
Current antiretroviral treatment can induce significant and sustained virological and immunological responses in HIV-1-infected persons over at least the short- to mid-term.
In this study, long-term immune reconstitution was investigated during highly active antiretroviral therapy.
Patients enrolled in the INCAS study in The Netherlands were treated for 102 weeks (range 52-144 weeks) with nevirapine (NVP) + zidovudine (ZDV) (n = 9), didanosine (ddl) + ZDV (n = 10), or NVP + ddl + ZDV (n = 10). Memory and naïve CD4+ and CD8+ T cells were measured using CD45RA and CD27 monoclonal antibodies (mAb), T-cell function was assayed by CD3 + CD28 mAb stimulation, and plasma HIV-1 RNA load was measured by ultra-direct assay (cut-off < 20 copies/ml).
Compared to both double combination regimens the triple combination regimen resulted in the most sustained increase in CD4+ T cells (change in CD4+, + 253 x 10(6) cells/l; standard error, 79 x 10(6) cells/l) and reduction of plasma HIV-1 RNA. In nine patients (31%) (ddl + ZDV, n = 2; NVP + ddl + ZDV, n = 7) plasma HIV-1 RNA levels remained below cut-off for at least 2 years. On average, these long-term virological responders demonstrated a significantly higher increase of naïve and memory CD4+ T cells (P = 0.01 and 0.02, respectively) as compared with patients with a virological failure, and showed improved T-cell function and normalization of the naïve; memory CD8+ T-cell ratio. However, individual virological success or failure did not predict the degree of immunological response. T-cell patterns were independent of baseline CD4+ T-cell count, T-cell function, HIV-1 RNA load or age. Low numbers of naïve CD4+ T cells at baseline resulted in modest long-term naïve T-cell recovery.
Patients with prolonged undetectable plasma HIV-1 RNA levels during antiretroviral therapy do not invariably show immune restoration. Naïve T-cell recovery in the setting of complete viral suppression is a gradual process, similar to that reported for immune recovery in adults after chemotherapy and bone marrow transplantation.
目前的抗逆转录病毒治疗至少在短期至中期内可使HIV-1感染者产生显著且持续的病毒学和免疫学反应。
本研究调查了高效抗逆转录病毒治疗期间的长期免疫重建情况。
荷兰INCAS研究中的患者接受奈韦拉平(NVP)+齐多夫定(ZDV)(n = 9)、去羟肌苷(ddI)+ZDV(n = 10)或NVP+ddI+ZDV(n = 10)治疗102周(范围52 - 144周)。使用CD45RA和CD27单克隆抗体(mAb)检测记忆性和初始CD4+及CD8+ T细胞,通过CD3 + CD28 mAb刺激检测T细胞功能,采用超直接检测法测量血浆HIV-1 RNA载量(临界值<20拷贝/ml)。
与两种双联治疗方案相比,三联治疗方案使CD4+ T细胞增加最为持续(CD4+变化量为+253×10⁶个细胞/升;标准误为79×10⁶个细胞/升),并降低了血浆HIV-1 RNA水平。9例患者(31%)(ddI + ZDV组2例;NVP + ddI + ZDV组7例)血浆HIV-1 RNA水平至少2年保持在临界值以下。平均而言,与病毒学治疗失败的患者相比,这些长期病毒学应答者的初始和记忆性CD4+ T细胞增加显著更高(分别为P = 0.01和0.02),且T细胞功能改善,初始/记忆性CD8+ T细胞比例恢复正常。然而,个体病毒学治疗成功或失败并不能预测免疫反应程度。T细胞模式与基线CD4+ T细胞计数、T细胞功能、HIV-1 RNA载量或年龄无关。基线时初始CD4+ T细胞数量少导致长期初始T细胞恢复适度。
抗逆转录病毒治疗期间血浆HIV-1 RNA水平长期不可检测的患者并非都能实现免疫恢复。在完全病毒抑制情况下初始T细胞的恢复是一个渐进过程,类似于化疗和骨髓移植后成人免疫恢复的情况。